<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02306590</url>
  </required_header>
  <id_info>
    <org_study_id>LIPCAL-ALS</org_study_id>
    <nct_id>NCT02306590</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to investigate the survival time (the time from
      randomization until death or date of end of the study) compared between control group and
      experimental group.

      This is a prospective, multicenter, randomized, stratified, parallel-group, double-blind
      trial comparing placebo with high caloric fatty diet for drinking as add-on therapy to 100 mg
      riluzole in amyotrophic lateral sclerosis (ALS) in 200 enrolled patients. For entry, the El
      Escorial Criteria for the diagnosis of ALS will be used. The patients have to be stable on
      riluzole at least 4 weeks prior to randomization.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival in ALS-patients with study intervention compared to placebo</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of total ALS functional rating scale revised (ALSFRS-R)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of individual quality of life (SEIQoL)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the slow vital capacity (sVC)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tracheostomy or death (combined)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Body Mass Index (BMI)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Appetite-Score, Council of Nutrition appetite questionnaire (CNAQ)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Study Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High caloric fatty diet for drinking (100% lipids, 4.5 kcal/ml) 405 kcal/90 ml/day in addition to daily food intake and standard of care; corresponding to an additional intake of 45 g fat per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo drinking solution 8 kcal/90ml/day in addition to daily food intake and standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calogen</intervention_name>
    <arm_group_label>Study Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Possible, probable (clinically or laboratory supported) or definite ALS according to
             the revised version of the El Escorial criteria (Brooks et al. 2000)

          -  Disease duration &lt; 36 months

          -  Vital capacity of more than 50% of normal (defined as slow vital capacity, best of
             three measurements)

          -  Age ≥18 years

          -  Continuously treated with 100 mg riluzole daily for at least four weeks

          -  Capable of thoroughly understanding all information given and giving full informed
             consent according to GCP

          -  Willing to complete a diet questionnaire throughout participation in the study

        Exclusion Criteria:

          -  Simultaneous participation in another interventional clinical study

          -  Previous participation in a drug clinical trial where last intake of the trial drug
             was within the last 12 weeks

          -  Known sensitivity or intolerance to rape oil or sunflower oil, or components thereof

          -  Tracheostomy

          -  Patients with gastrostomy

          -  Pregnancy or breastfeeding

          -  Any medical condition known to have an association with motor neuron dysfunction which
             might confound or obscure the diagnosis of ALS

          -  Presence of any concomitant life-threatening disease or impairment likely to interfere
             with functional assessment.

          -  Evidence of a major psychiatric disorder or clinically evident dementia precluding
             evaluation of symptoms.

          -  Liable to be not cooperative or comply with study requirements as assessed by the
             investigator, or unable to be reached in the case of emergency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert C. Ludolph, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Ulm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology, University of Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Rostock</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>D-18147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Medical School Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Halle-Wittenberg</name>
      <address>
        <city>Halle/Saale</city>
        <state>Sachsen-Anhalt</state>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, TU Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Jena</name>
      <address>
        <city>Jena</city>
        <state>Thueringen</state>
        <zip>D-07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Humboldt University</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik Bergmannsheil</name>
      <address>
        <city>Bochum</city>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department für Neurologie - Klinik für Schlafmedizin und Neuromuskuläre Erkrankungen Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, DKD HELIOS Klinik</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2014</study_first_submitted>
  <study_first_submitted_qc>December 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2014</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Albert Christian Ludolph, Prof.</investigator_full_name>
    <investigator_title>Departement of Neurology</investigator_title>
  </responsible_party>
  <keyword>amyotrophic lateral sclerosis</keyword>
  <keyword>survival time</keyword>
  <keyword>ALS Functional Rating Scale</keyword>
  <keyword>quality of life</keyword>
  <keyword>survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

